Informations générales (source: ClinicalTrials.gov)
Micro Array Analysis in Preeclampsia
Interventional
N/A
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
juin 2011
janvier 2021
29 juin 2024
Preeclampsia is a frequent pathology. His etiology is doubtful.
Targets :
The study target is to identify a risk of preeclampsia group obtained with transcriptom
analysis from circulating peripheric cells.
Design:
Multidisciplinary study (Gynaecology-Obstetric, Immunology, North CIC).
The study of the transcriptional history of peripheral blood cells of 2patients groups:
- A patient group with a preeclampsia before 34 SA
- A patient group with a normal pregnancy paired on main confusion factors. Blood
sampling will be collected at the diagnosis and 8 weeks after delivery.
Results and perspectives
- Obtain a transcriptionnal signature of preeclampsia
- To identify new mechanism of the disease
- Identification of a specific transcriptom analysis with the comparison after
delivery For long-term, the target is to identify risk patient in order to conduct
easily preventive clinical trials in preeclamsia (primary prevention) and to
consider a specific follow-up for risk patients.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Assistance Publique Hopitaux de Marseille - 13354 - Marseille - France | florence bretelle | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- A prééclampsie (blood pressure superior to 140 mmHg and to 90 mmHg) and at least a
cross of protein in the strip and/or more of 300mg / 24h after 20 LIMITED COMPANIES
and before 34 limited companies.
- An informed consent signed by the patient will necessarily have to be obtained.
- Woman having been taken care during the pregnancy or at the time of the
childbirth(delivery) by one of the participating teams to the current project.
- Caucasian Patient
- Wait primigeste and nullipare
- A prééclampsie (blood pressure superior to 140 mmHg and to 90 mmHg) and at least a
cross of protein in the strip and/or more of 300mg / 24h after 20 LIMITED COMPANIES
and before 34 limited companies.
- An informed consent signed by the patient will necessarily have to be obtained.
- Woman having been taken care during the pregnancy or at the time of the
childbirth(delivery) by one of the participating teams to the current project.
- Caucasian Patient
- Wait primigeste and nullipare
- Major Patient protected by the law.
- Patient deprived of freedom for administrative or judicial reasons.
- Patient not benefiting from a national insurance scheme.
- Refusal of the patient to participate in the study.
- Not Caucasian Patient
- Multipare Wait
- Multiple Pregnancy
- Existence of foetal deformation explaining a delay of growth or a foetal death in
utero.
- Age 18 years and > 40 years.
- Absence of written consent or impossibility to receive the written consent (language
or understanding).